ProciseDx has obtained de novo clearance from the US Food and Drug Administration (FDA) for its therapeutic drug monitoring (TDM) tests for drugs adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis).

Procise ADL and Procise IFX assays are intended for quantifying adalimumab (ADL) and infliximab (IFX) in patients suffering with inflammatory bowel diseases (IBD).

Designed to be performed using serum, the tests generate a quantitative result within five minutes.

Based on time-resolved fluorescence (Förster) resonance energy transfer immunoassays, the Procise TDM assays can determine drug levels in patients undergoing infliximab and adalimumab therapy.

The assays leverage the patented ProciseDx Analyser and Lumiphore chemistry to determine the drug levels.

The ProciseDx technology allows on-site TDM testing in laboratories at hospitals and clinical laboratories.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ProciseDx CEO Larry Mimms said: “Currently, results for drug concentrations for infliximab and adalimumab take days and require shipment to expensive third-party laboratories.

“ProciseDx enables physicians and hospital laboratorians to take control of biologics TDM through on-site testing.”

The company plans to commercially launch these drug monitoring tests in the fourth quarter of this year.

As per the Crohn’s and Colitis Foundation’s cost study, biologics such as Humira and Remicade are the significant drivers of expenses in IBD treatment. Drug costs for these patients using biologics are between $20,000 and $60,000 per annum.

In November last year, the company secured approval from the FDA for the ProciseDx analyser and the immunoassay for C-Reactive protein (CRP).

ProciseDx assays, which have a CE Mark, have been sold for TDM tests in Europe and the Middle East since 2021.